despit stock fade throughout day think non-inferior
consist trend favor align optimist base case
often difficult pinpoint investor expect alexion think
investor whole concern binari event risk
associ trial expect gain persist today
given data provid incent patient clinician convert
reduc risk downsid soliri scenario competit emerg
come year look forward see improv lt visibl
franchis note see averag annual top line growth
driven allevi trial headwind soliri roll-out
gmg strensiq/kanuma growth sustain double-digit lt growth
less visibl need driven re-build alxn pipelin
overhang biosimilar competit remain tabl threat
roch possibl reduc sign hypersensit reaction
competitor data weve seen far measur
continu see greatest lt risk alexion come soliri biosimilar
price competit think mani emerg market eu territori may
preferenti steer new patient toward biosimilar soliri even
appear offer overal improv profil think eu patient
migrat extrem unlik convert back biosimilar
us sale think share like hold well
time biosimilar entri remain unclear model us
valuat reiter outperform rate increas tp
increas po valuat
base blend dcf project risk thesi includ clinic
trial failur novel therapeutics/biosimilar
valuat metric
number share
price month
 close
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
charl martineau univers toronto assum roughli pariti price soliri pnh price channel
check suggest high interest convert patient us
model assum year eu emerg market roughli
compar price plu cost save associ reduc infus improv
administr support assumpt market convers year
alexion biotechnolog compani focus research
develop commerci therapeut rare diseas
alexion drug soliri use treat patient complement
mediat disord product includ strensiq
price rate outperform target price analyst tin auster
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
cash-flow financ activ
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
 close
establish superior efficaci soliri pnh
trial posit nmo data increas pipelin valu
fail establish non-inferior efficaci soliri failur
nmo decreas pipelin valu
compani mention price
